McLaughlin Asset Management Inc. Takes Position in Stryker Corporation $SYK

McLaughlin Asset Management Inc. bought a new position in Stryker Corporation (NYSE:SYK) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 2,183 shares of the medical technology company’s stock, valued at approximately $767,000.

Several other institutional investors and hedge funds also recently bought and sold shares of SYK. Norges Bank bought a new position in shares of Stryker in the fourth quarter worth about $1,822,272,000. Wellington Management Group LLP grew its stake in shares of Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after acquiring an additional 1,198,665 shares during the period. Corient Private Wealth LLC grew its stake in shares of Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after acquiring an additional 1,146,998 shares during the period. Alliancebernstein L.P. increased its holdings in Stryker by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after acquiring an additional 741,542 shares in the last quarter. Finally, Strive Asset Management LLC bought a new stake in Stryker during the 3rd quarter worth approximately $227,389,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 over the last 90 days. Corporate insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of recent analyst reports. Citigroup dropped their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. UBS Group decreased their price objective on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 17th. Robert W. Baird set a $385.00 target price on shares of Stryker in a research note on Friday, May 1st. Leerink Partners cut their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Finally, Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $395.33.

Stryker Price Performance

SYK stock opened at $308.62 on Friday. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The company’s fifty day moving average price is $314.43 and its 200-day moving average price is $341.94. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The company has a market capitalization of $118.31 billion, a PE ratio of 35.72, a price-to-earnings-growth ratio of 1.93 and a beta of 0.78.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.Stryker’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts anticipate that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.